Lenalidomide enhances myeloma-specific T-cell responsesin vivoandin vitro-Reference-Cited by-同舟云学术

Lenalidomide enhances myeloma-specific T-cell responsesin vivoandin vitro

Published:2016-02-18 Issue:5 Volume:5 Page:e1139662
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Krämer Isabelle,Engelhardt Melanie,Fichtner Sabrina,Neuber Brigitte,Medenhoff Sergej,Bertsch Uta,Hillengass Jens,Raab Marc-Steffen,Hose Dirk,Ho Anthony D.,Goldschmidt Hartmut,Hundemer Michael

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.1080/2162402X.2016.1139662

Reference35 articles.

1. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

2. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

3. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

4. Generation of Antitumor Invariant Natural Killer T Cell Lines in Multiple Myeloma and Promotion of Their Functions via Lenalidomide: A Strategy for Immunotherapy

5. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bispecific antibodies in the treatment of multiple myeloma;Blood Cancer Journal;2024-09-12

2. Evaluation of granulocyte colony-stimulating factor effect on the expression of inhibitory receptors by T cells in multiple myeloma;Medical Immunology (Russia);2024-07-27

3. SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2024-03

4. Bispecific Antibodies in Hematological Malignancies: A Scoping Review;Cancers;2023-09-14

5. Chimeric antigen receptor T‐cell therapy in hematologic malignancies: Successes, challenges, and opportunities;European Journal of Haematology;2023-08-06